Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome
Authors:
Open Access
- 10 March 2020
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 19 (1) , 1-14
Abstract
Background: The triglyceride glucose (TyG) index, a simple surrogate estimate of insulin resistance, has been demonstrated to predict cardiovascular (CV) disease morbidity and mortality in the general population and many patient cohorts. However, to our knowledge, the prognostic usefulness of the TyG index after percutaneous coronary intervention (PCI) in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) has not been determined. This study aimed to evaluate the association of the TyG index with adverse CV outcomes in patients with T2DM and ACS who underwent PCI. Methods: The TyG index was calculated using the formula ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. The primary endpoint was the composite of all-cause mortality, non-fatal stroke, non-fatal myocardial infarction, or unplanned repeat revascularization. The association between the TyG index and adverse CV outcomes was assessed by Cox proportional hazards regression analysis. Results: In total, 776 patients with T2DM and ACS who underwent PCI (mean age, 61 ± 10 years; men, 72.2%) were included in the final analysis. Over a median follow-up of 30 months, 188 patients (24.2%) had at least 1 primary endpoint event. The follow-up incidence of the primary endpoint rose with increasing TyG index tertiles. The multivariate Cox proportional hazards regression analysis adjusted for multiple confounders revealed a hazard ratio for the primary endpoint of 2.17 (95% CI 1.45–3.24; P for trend = 0.001) when the highest and lowest TyG index tertiles were compared. Conclusions: The TyG index was significantly and positively associated with adverse CV outcomes, suggesting that the TyG index may be a valuable predictor of adverse CV outcomes after PCI in patients with T2DM and ACS.Keywords
Funding Information
- National Key Research and Development Program of China (2017YFC0908800)
- Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150601)
- Beijing Municipal Administration of Hospitals’ Mission plan (SML20180601)
- Beijing Municipal Health Commission - “Project of Science and Technology Innovation Center” (PXM2019_026272_000006, PXM2019_026272_000005)
This publication has 43 references indexed in Scilit:
- Arterial stiffness predicts risk for long-term recurrence in patients with type 2 diabetes admitted for acute coronary eventDiabetes Research and Clinical Practice, 2013
- Tissue–Specific Insulin Signaling, Metabolic Syndrome, and Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Insulin Resistance, Hyperglycemia, and AtherosclerosisCell Metabolism, 2011
- TyG index performs better than HOMA in a Brazilian population: A hyperglycemic clamp validated studyDiabetes Research and Clinical Practice, 2011
- The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy SubjectsMetabolic Syndrome and Related Disorders, 2008
- Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular DiseaseJACC, 2007
- Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery diseaseAmerican Heart Journal, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Insulin resistance and thrombosis: a cardiologist’s viewThe American Journal of Cardiology, 1999
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976